Trials / Unknown
UnknownNCT05701384
Lazertinib 160mg in EGFR T790M NSCLC
A Phase II Study for the Evaluation of the Feasibility of Lazertinib 160mg Per Day in Patients With EGFR T790M Mutant Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 117 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lazertinib | 160mg po qd |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2024-01-31
- Completion
- 2025-01-31
- First posted
- 2023-01-27
- Last updated
- 2023-01-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05701384. Inclusion in this directory is not an endorsement.